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Abstract 
 
 
Molecular virological techniques have rapidly replaced cell culture as the diagnostic 
tool of choice across NHS laboratories. This thesis studies two of the commonest causes 
of CNS viral infections in infants less than 90 days of age to determine whether the 
introduction of Polymerase Chain Reaction (PCR) based techniques have impacted 
significantly on their management and epidemiology.  
 
Congenital CMV (cCMV) is the commonest congenital infection in the UK and a 
leading cause of sensorineural hearing loss (SNHL). In the absence of a screening 
programme the great majority are detected in early childhood outside the time when 
antiviral therapy has been shown to be effective. This thesis describes a series of 
coordinated pilot studies that suggest that it is potentially feasible to integrate testing for 
cCMV using salivary PCR into the Newborn Hearing Screening Programme (NHSP) 
and start appropriate antiviral management within the first month of life. A programme 
of work that needs to be conducted before potential national implementation is also 
outlined. Conventional molecular techniques were used to characterise the variation of 
five genetic loci of CMV in congenitally infected infants to better understand the 
current and future medical interventions available. 
 
Enterovirus (EV) infections most commonly infect young infants. PCR has been shown 
 4 
to detect viruses with greater accuracy than cell culture. National data over a 10 year 
surveillance period were analysed to demonstrate a seven fold increase in viral 
meningo-encephalitis diagnosis rates associated with increased use of PCR. 
Enteroviruses accounted for 92% of all cases of viral meningo-encephalitis in those 
aged less than 90 days. The year on year increase in EV infections coincided with 
increasing PCR-based laboratory diagnosis, which accounted for 36% of reported cases 
in 2000 and 92% in 2011. These data provided the rationale for the design and 
implementation of a British Paediatric Surveillance Unit (BPSU) study characterising 
the burden of EV and human parechovirus meningitis in children aged less than 90 
days.  
 
This thesis supports the notion that advances in molecular virology can significantly 
inform the investigation and management of CNS viral infections (as exemplified by 
cCMV) and alter the apparent epidemiology (as exemplified by EV infections in infants 
less than 90 days old). 
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Chapter 1 
Introduction 
 
1.1 Cell Culture v Polymerase Chain Reaction 
 
Growing viruses in cell culture started in the 1950’s gaining a Nobel prize for the 
discoverers and enabling production of live attenuated vaccines including against polio 
(1). 
 
The use of cell culture to determine viral of specimens relies on growing live viruses to 
enable detection. Shell vial culture, where viral growth is measured by antigen 
detection, was shown to reduce the time to detect slowly growing viruses such as 
cytomegalovirus (CMV) to 24 hours and was adopted into clinical practice from the 
early 1980’s (2,3). The gold standard in the diagnosis of congenital CMV infection has 
been viral culture of urine (4,5).  
 
Enteroviruses (EV) are shed in the oropharynx and faeces and can be detected in blood, 
cerebrospinal fluid (CSF), urine, or tissues in cases of severe disease. Viral culture has 
been the “gold standard” for the diagnosis of EV infection in different clinical 
specimens such as faeces, throat swabs and CSF. Enteroviruses may be shed for weeks 
after the acute infection so isolation of the virus from stool needs to be interpreted with 
caution. Viral culture enables identification of the serotype causing disease and remains 
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an important epidemiological surveillance tool. Obtaining positive EV or CMV culture 
results often comes too late to influence clinical decision making. 
 
CMV DNA detection using PCR is automated, rapid and reproducible (6). Real time 
PCR can be used to provide greater accuracy to detect CMV. CMV PCR, with the 
capacity for real time quantification of viral genomes, has been increasingly used in 
clinical practice since the early 2000’s (2). A number of studies have shown that CMV 
PCR is of greater sensitivity compared to urine culture in immunosuppressed patients 
and solid organ transplant (SOT) recipients (2,7–10).  
 
The sensitivity of cell culture for enteroviruses ranges between 53%-75% and they 
usually take 4-8 days to grow (11–14). A prospective national surveillance study 
conducted by de Louvois and colleagues between 1985-7 assessed the incidence of 
meningitis in infants (15). Viral infection was confirmed in only 4% (16/423) of 
meningitis cases in infants less than one month. However, 92/423 (22%) of CSF 
samples showed evidence of pleiocytosis (CSF white cell count >20 x 106/l) but no 
pathogen was grown when using cell culture. A study conducted between 2011-2012 in 
three UK paediatric referral centres aimed to assess the aetiology of childhood 
meningitis (16). This study, conducted almost 30 years later, identified no aetiology in 
35 out of 84 (42%) of children with pleiocytosis. 
 
Real time PCR is replacing viral culture across laboratories as the diagnostic tool of 
choice to identify viruses (17–20). PCR methods only require small amounts of 
biological samples, can be used to test different samples using batched testing and 
deliver results within 24 hours of samples arriving in the laboratory. Real time PCR also 
allows quantitative analysis with, for example, comparison of fluorescence threshold 
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(CT) values or determination of copy numbers relative to a standard curve of known 
concentrations.  
 
PCR methodology was applied to detect EV soon after it was first developed (21,22). 
PCR based assays use a reverse transcription step to convert RNA to cDNA (RT-PCR) 
and are able to detect almost all EV serotypes because they share common genomic 
sequences. Several studies have shown that PCR is able to detect EVs with greater 
sensitivity rates ranging between 92 - 96% and specificity rates of 93 – 96% compared 
to viral culture (23–28). One study has shown that at least two thirds of all cerebrospinal 
fluid (CSF) specimens from meningitis patients who had negative results by cell culture 
had positive results by EV-PCR (16). RT-PCR is at least as sensitive and certainly more 
rapid than virus recovery in cell culture (29). 
 
Congenital CMV and enteroviruses are both important viral causes of CNS infection in 
infants less than 90 days.  This thesis will discuss how molecular techniques including 
PCR can be used to inform the management of cCMV and epidemiology of enterovirus 
infections in this age group. 
 
1.2 Cytomegalovirus (CMV) 
 
1.2.1 Epidemiology  
 
Vertical transmission of CMV infection can occur through three main routes: (i) 
intrauterine; (ii) intrapartum and (iii) post-natal. Intrauterine transmission is the most 
important route as it may result in major neurological sequelae. Primary maternal 
infection, maternal reinfection with a different viral strain or reactivation of latent 
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maternal infection can all cause in utero transmission. Maternal CMV infection in 
seronegative women with primary infection during pregnancy is transplacentally 
transmitted to the fetus in 32% of cases (30). However, maternal to fetal transmission 
occurs in only 1% - 2% of seropositive cases which is either due to reactivation or 
reinfection with a new strain (30,31).  
 
Congenital CMV (cCMV) is the most common congenital infection in the U.K. Data 
from studies conducted over 20 years ago show that approximately 0.3% of live births 
in the U.K are infected (32,33). Congenital CMV is the leading  non genetic cause of 
sensorineural hearing loss (SNHL) (34,35).  Approximately 12.7% of infected newborns 
are symptomatic at birth (34). Around 13.5% of infants who are asymptomatic then 
develop sequelae including SNHL in childhood (34). The most recent national 
prospective surveillance study in the U.K was conducted by the British Paediatric 
Surveillance Unit between 2001 – 2002 (36). This study only recorded 86 confirmed 
cases which gives a prevalence of 0.06 per 1000 live births. The authors of the BPSU 
study noted that challenges in case ascertainment arose due to difficulty in confirming 
congenital infection (obtaining samples within three weeks of life), diagnosing cases 
(the majority are asymptomatic and not reported) and differences in local unit protocols 
(some neonatal units screen all newborns on admission but most do not). Since 2001, 
there have been no further attempts over to define the incidence of cCMV in the U.K. 
 
Antiviral treatment has been shown in a Randomised Control Trial to prevent further 
hearing loss and improve developmental outcomes when started in the first month of 
life in babies born with central nervous system (CNS) disease (37). At present in the UK 
testing for cCMV only occurs after a newborn is confirmed with hearing loss, and this 
typically occurs too late for treatment to be offered or effective. Testing saliva is 
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essentially 100% sensitive for detection of the virus but there is no NHS framework to 
take saliva samples from every baby at birth or for laboratories to efficiently process 
them. Integrating saliva testing for cCMV into the routine newborn hearing test would 
ensure that affected newborns could be treated within the time during which treatment is 
known to work. This will reduce the overall burden of childhood deafness (and 
developmental disability), and overall costs to the NHS. 
 
1.2.2 Clinical disease 
 
 
1.2.2.1 Symptomatic infection   
 
The typical physical signs of symptomatic disease include blueberry muffin rash (due to 
extramedullary haematopoiesis), petechiae (associated with underlying 
thrombocytopenia), Intrauterine Growth Restriction (IUGR), microcephaly, 
hepatosplenomegaly and jaundice. Laboratory results are consistent with hepatic and 
reticuloendothelial involvement. Biochemical abnormalities can include conjugated 
hyperbilirubinaemia, thrombocytopaenia and elevated hepatic transaminases in the 
majority of symptomatic newborns (38). CNS features include seizures, focal 
neurological findings, chorioretinitis, optic atrophy, pigmentary retinopathy and 
strabismus (39). Mortality is reported in 4-12% of those symptomatic at birth 
(38,40,41).  
 
1.2.2.2 Sensorineural hearing loss 
 
CMV related hearing loss can be either unilateral or bilateral and may be profound. 
SNHL most frequently affects young children coinciding with the critical period for 
speech and language development.  SNHL has a lifelong impact on the individual, 
significantly impairs quality of life and adversely affects future life outcomes. The 
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SNHL caused by cCMV is often progressive, worsening through early childhood (42). 
 
A retrospective Dutch study showed that CMV DNA was detected on Dried Blood Spot 
(DBS) of 8% (14/179) children aged between 3 – 5 years of age with permanent 
childhood hearing impairment and in 23% (9/39) who had profound hearing loss (43). 
Other retrospective cohort studies have reported rates between 15-40% (44–46). A 
systematic review of studies of children with cCMV showed that approximately 14% of 
children infected with cCMV will develop SNHL of some type and 3-5% will develop 
bilateral moderate to profound SNHL (47). The review found that 15-20% of all cases 
of bilateral to profound SNHL are due to cCMV. 
 
The risk of SNHL is highest in newborns with symptomatic disease. However, 
approximately two thirds of the overall burden of CMV associated SNHL lies in the 
asymptomatic group due to their higher abundance in the population (48). A 
retrospective cohort study found rates of SNHL in 22-65% of babies with symptomatic 
CMV compared to 6-23% of those asymptomatic at birth (49).  A meta-analysis of 
global rates of CMV related SNHL found overall hearing loss in around 35% compared 
to 11-12% of those born with symptomatic and asymptomatic cCMV at birth 
respectively (34).   
 
1.2.2.3 Asymptomatic infection   
 
Congenital CMV is most commonly asymptomatic. Approximately 10% of 
asymptomatic children will develop SNHL over the first 5–7 years of life (35). Hearing 
loss can be bilateral and is often progressive or with delayed onset therefore requiring 
prolonged audiological follow up (35). Because hearing is often normal at birth, only 
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50% of cases of SNHL caused by CMV are expected to be detected by neonatal hearing 
screening programmes (35). Asymptomatic newborns should therefore be regularly 
followed up till the age of 6 years to identify late onset hearing loss (50). 
 
The NHSP is part of routine neonatal care in the U.K. and successfully screens over 
95% of newborns in the UK. Integrating a targeted screening programme for cCMV 
into an already successful screening programme would be feasible, enable quality 
evaluation, rigorous follow up of infected newborns and enhance the diagnostic 
pathway along with potential cost savings.  Integrating detection of congenital CMV 
through the NHSP would consolidate the link between screening, identification and 
management of the virus within standard NHS processes. Chapters 2 of this thesis 
proposes that no other viable screening options exist. Chapter 3 demonstrates that 
integrating testing for c CMV into the NHSP is effective.  
 
1.2.3 Treatment  
 
A recent survey of clinicians revealed significant variation amongst clinicians in the 
management of newborns with cCMV (Personal communication). I led a 
multidisciplinary team of audiologists, paediatricians and virologist to publish the first 
evidence based management guidelines to treat cCMV in 2011 (50). A RCT 
demonstrating 6 months of treatment using valganciclovir if starred in the first month of 
life in symptomatic newborns was published in 2015 (37). Chapter 7 describes updated 
management guidelines that include data from this recently published RCT. The 
guidelines recommend that only symptomatic newborns are treated with valganciclovir 
if started in the first month of life. Guidance is also provided regarding safety 
monitoring and follow up of both symptomatic and asymptomatic newborns.  It is 
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anticipated that these guidelines will be widely adopted across neonatal units in the UK 
and provide a useful template for clinicians to treat infants with symptomatic disease.
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1.2.3.1 Antivirals in clinical use 
 
Data from a recently completed placebo-controlled, double blind, randomized study 
comparing 6 weeks versus 6 months of valganciclovir conducted by the Collaborative 
Antiviral Study Group (CASG 112) were recently published (37). The primary 
objectives of the study were to compare hearing outcomes, safety profiles, assess 
neurological outcomes and monitor CMV viral loads in symptomatic neonates up to one 
month of life who received 6 weeks versus 6 months of VGCV. In total, 109 subjects 
were recruited between 2008 and 2011. The results showed superior language 
(p=0.0046) and receptive communication (p=0.0031) scores at 24 months in the 6-
month treatment group compared with the 6-week group.  During the first 6 weeks of 
treatment 19.3% of subjects experienced severe neutropenia (<0.75 x 109/L). 21.3% of 
subjects between week 6 and month 6 who were treated with valganciclovir had severe 
neutropaenia compared to 26.5% who were on placebo (p=0.6353). The authors 
concluded that 6 months of oral valganciclovir treatment in symptomatic newborns, 
when started less than a month of age, improved audiological and neurodevelopmental 
outcomes to at least 2 years of age. Moreover, fewer participants had neutopaenia in the 
first 6 weeks of treatment with oral valganciclovir (19.3%) than compared to the 
previous RCT which evaluated ganciclovir efficacy (63%).  No other phase III 
treatment trials are being conducted to assess treating cCMV.  
 
1.2.3.2 Vaccine candidates  
 
Development of a vaccine against cCMV infection is a major public health priority (51). 
Three phase II vaccine trials have been conducted in the last six years with promising 
results (52–54). The most recent vaccine trials have used glycoprotein B (gB) as a 
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vaccine target. A phase II RCT recruited 70 seronegative and 70 seropositive patients 
awaiting kidney or liver transplant (53). Patients received either gB vaccine with MF59 
adjuvant or placebo, each given at baseline, 1 month and 6 months later. Glycoprotein B 
antibody titres were raised in both seronegative (geometric mean titre 12 537 (95% CI 
6593–23 840) versus 86 (63–118) in recipients of placebo recipients; p<0.0001) and 
seropositive (118 395; 64 503–217 272) versus 24 682 (17 909–34 017); p<0.0001) 
recipients of vaccine. Seronegative recipients with seropositive donors had a shorter 
duration of viremia (p=0.0480) and the number of days of treatment with ganciclovir or 
valganciclovir was reduced compared to placebo.  
 
1.2.3.3 Polyclonal and monoclonal antibody studies 
 
A recent randomised double bind placebo controlled trial enrolled 124 pregnant women 
with primary CMV infection between 5 – 26 weeks gestation (55). Women were 
randomised to receive either 100U/kg HIG or placebo every 4 weeks till 36 weeks or till 
CMV detection in the amniotic fluid. Treatment started within 6 weeks after the onset of 
infection. The rate of congenital infection was 30% in the treatment group compared to 
44% in those who received placebo (p=0.13). Moreover, obstetric adverse events 
(preterm delivery, IUGR, hepatitis cholestasis and postpartum eclampsia) occurred in 
13% of the HIG group compared to only 2% in those receiving placebo. The authors 
concluded that HIG did not show any statistical difference in prevention of cCMV in 
123 women who received either HIG or placebo (55).
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1.2.3.4 Genetic variation and implications for medical intervention   
 
Gaps in understanding the molecular epidemiology of cCMV act as one of the barriers 
to successfully implementing a vaccination programme to protect infants from 
congenital disease (56). A successful vaccine to protect against cCMV would need to 
consider the genotypic variation of CMV including in glycoprotein B gene. It is also 
unclear whether one strain of virus has a predilection for one body compartment over 
another strain. Distinct differences in CMV strains might occur between different 
compartments and could help explain variation in disease outcome or viral transmission.  
No data exist detailing whether the virus segregates with the patient or the body 
compartment. 
 
Chapter 6 provides novel data which contributes to our understanding of the molecular 
epidemiology of therapeutic targets for cCMV including antiviral treatment, vaccine 
targets and regions for monoclonal antibody binding.  
 
1.2.3.4.1 UL97 
 
The Virology Immunity Congenital CMV (VICC) study started recruitment in 2008 
across 9 tertiary paediatric centres in the UK (57). The primary objectives were to study 
the cellular immunity and viral loads in blood, saliva and urine of infants with cCMV. 
To date, this is the only known study to prospectively collect blood, saliva and urine 
samples in infected infants treated with 42 days ganciclovir therapy. The study showed 
that CMV viral loads in blood, saliva and urine fell at the point ganciclovir was started 
in 17 cCMV infected infants (57). However, a rebound in viral load was seen within 1 
week of stopping treatment in 4 out of 8, 6 out of 9 and 1 out of 5 patients with blood, 
urine and saliva samples available respectively with corresponding median increase in 
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VL being 0.52, 1.03 and 2.05 log10.  
 
There had previously been no studies have yet evaluated whether the rebound in viral 
load after 42 days of therapy is due to mutations in the UL97 gene leading to resistance 
to ganciclovir. Results from the Virology Immunity Congenital CMV (VICC) study 
demonstrated a decline in CMV viral loads in blood, saliva and urine following 42 days 
treatment with ganciclovir which had been administered in 17 infected newborns. A 
rebound in viral load can be seen, particularly in the urine and saliva compartments, 
when treatment stops at day 42 (Figure 1). 
 
Data presented in chapter 6 are the first to demonstrate that six weeks of treatment with 
ganciclovir does not frequently select for resistance in the UL97 gene. These results, in 
part, have helped to inform evidence based management guidelines described in chapter 
7. 
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Figure 1: Mean viral load over time in different body fluids in 17 babies treated for congenital 
CMV demonstrating decline in viral loads upon starting treatment with ganciclovir and rebound 
recorded in each body compartment upon treatment stopping at day 42. Data obtained from 
Viral load and Immunity on Congenital CMV study with permission from Dr S. Luck. 
(Error bars represent standard deviation). 
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1.2.3.4.2   Glycoprotein B  
 
Glycoprotein B has been used in recent phase II trials in women of childbearing age and 
solid organ transplant recipients as a target for vaccines (53,54). 
 
Glycoprotein B is a major envelope glycoprotein encoded by the UL55 gene, which is 
implicated in virus entry, cell to cell transmission and fusion of infected cells. It is a 
major target for both humoral and cellular immune responses. Four distinct genotypes 
(gB 1 – 4) have been identified in cCMV infected infants (58).  Studies have shown co-
infection with multiple strains occur (59). Studies in transplant patients have suggested 
that mixed gB genotypes may be associated with more severe clinical disease (60).  
 
Chapter 6 shows that significant genetic variation exists in gB. These are important 
findings which would would need to be considered in future vaccine development. 
Moreover, these results indicate infants may be infected with more than one strain of 
virus through transplacental passage. 
 
1.2.3.4.3    UL 128 – UL 131a  
 
The UL128-131a gene loci form a pentameric complex with gL and gH. The UL128-
131a region is a major determinant of virus entry and replication into epithelial cells. 
The gH/gL/UL28-131a complex induces early, highly potent and long lasting 
neutralising antibody responses to control virus dissemination in vivo (61). Studies have 
shown a correlation between neutralising antibody that is targeted at the gH/gL/UL128-
UL131a complex (62). The neutralising antibody response during primary infection has 
been directed against two or three gene products of the UL128-131a region (63).   
Sequence variation amongst different strains of CMV is explained due to the unusually 
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high variation of a subset of genes and may be a significant problem for developing 
antibody based programmes (64). Characterising the UL128-131a region is important in 
order to understand whether significant sequence variability exists which may make 
resistance to HIG therapy more likely.   
 
Results outlined in chapter 6 show that there were no changes in the binding site for 
monoclonal antibody. This would suggest that there should not be any reduction in 
binding affinity between monoclonal antibody against the virus. 
 
1.2.4 Diagnosis 
 
One of the initial studies conducted by Demmler and colleagues showed that PCR using 
primers to immediate early and late genes was 93% sensitive and 100% specific when 
testing samples from congenitally infected newborns (65). Another of the earlier 
studies, by Warren and colleagues, found that PCR was 89.2% sensitive and 95.8% 
specific when compared to standard tissue culture of saliva samples (66).  Higher 
sensitivities have been reported when regions with low genetic variability between 
strains have been targeted (67).  Nested PCR is time intensive and carries a risk of 
contamination but has higher sensitivity rates.  Urine can  inhibit the enzymes used in 
PCR assays and consequently deliver false negative results.  
 
1.2.4.1 Screening for cCMV 
 
There are no ongoing studies or systematic reviews that have assessed the effectiveness 
of integrating cCMV testing into the Newborn Hearing Screening Programme (NHSP).  
 
 
Identification of newborns with hearing loss but no other features of CMV disease 
would allow for enhanced audiological monitoring to detect hearing deficits early. 
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Language outcomes in infancy have demonstrably improved with hearing screening 
programmes (68). Prompt intervention of late onset hearing loss in early childhood, 
including early fitting of cochlear implants has been shown to improve language 
development (69). In the absence of routine testing at birth, the majority of 
asymptomatic newborns are missed so infection is only detected in early childhood 
when SNHL may be profound. Detecting cCMV in the newborn period could result in 
significant cost savings, avoid unnecessary diagnostic tests, minimise therapeutic 
interventions and provide parents with a cause for their newborns hearing loss (70). 
 
There is currently no national screening programme to detect cCMV. At present in the 
UK testing for cCMV only occurs after a newborn is confirmed with hearing loss, and 
this typically occurs too late for treatment to be offered or effective.  
 
Testing for cCMV using saliva by real time PCR is accurate, cheap, rapid and ensures 
prompt identification in the newborn thereby enabling antiviral treatment to be started 
in the first month. This will reduce the overall burden of childhood deafness (and 
developmental disability), and overall costs to the NHS. Integrating testing into the 
NHSP would enhance the diagnostic care pathway. It is estimated that an additional 113 
newborns will be identified and treated with CMV related SNHL through integrating 
salivary testing into the NHSP (71). 
 
Chapter 2 provides a comprehensive review of which strategies are available to test for 
cCMV and which future research areas need to be addressed before national 
implementation could be introduced (72). Chapters 3 and 4 attempt to provide data to 
answer some of the research questions proposed in chapter 2. 
 
Chapter 3 describes the BEST 2 study assessed the feasibility of integrating testing for 
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cCMV using salivary swabs into the NHSP in south west London over 6 months (73). 
Parents of newborns <22 days old who were referred after their initial newborn hearing 
for further audiological testing, were approached by hearing screeners to obtain a saliva 
sample for CMV DNA PCR. Hearing screeners completed a five point Likert 
psychometric questionnaire to assess their opinions on the feasibility of cCMV testing 
through the NHSP.  In total, 80% (203/255) newborns who were eligible had a saliva 
swab taken by the hearing screener. >99% results were delivered within the first month 
of life. Two newborns were identified with cCMV and both seen on day 10 of life by 
the paediatric specialist. All saliva samples tested delivered a result using real time 
PCR. All hearing screeners (20/20) stated that integrating testing for cCMV into the 
NHSP was a good idea and felt confident to perform this. This pilot study showed that it 
is feasible for hearing screeners to obtain saliva swabs to test for CMV DNA using real 
time PCR in newborns referred after their initial hearing screen. 
 
Chapter 4 describes results from a national survey of members of the British 
Association Paediatricians of Audiology (BAPA) and British Association of 
Audiovestibular Physicians (BAAP) to determine the service hurdles in managing 
newborns with cCMV related SNHL. Audiovestibular physicians stated that the time 
taken to manage the extra newborns identified through testing would place undue 
pressure on their service. These results are important in understanding how to develop 
any potential national screening programme. 
 
Chapter 5 reviews a novel approach to identify pCMV early in extremely preterm 
infants and using pre-emptive therapy to minimise adverse clinical outcomes. To my 
knowledge, this is the first published review to systematically describe how to identify 
and manage pCMV. Importantly, it also offers a unique approach to better detecting 
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pCMV on neonatal units and outlines where future research should be prioritised.  
 
 
1.3  Enteroviruses  
 
Conjugate vaccines against Neisseria meningitidis group C, Streptococcus pneumoniae 
and Haemophilus influenzae type b (Hib) have ensured that serious bacterial infections 
and bacterial meningitis are now a rare cause of disease in young infants and children 
(74–77). 
 
 Most cases of infant meningitis are now due to viral causes (78,79). Population based 
surveillance data published from the U.K show that mumps meningitis occurred in only 
0.35% of all cases during 2002 – 2006 with the virus less commonly identified since 
two doses of vaccine was introduced to the universal immunisation schedule in 1996 
(80). Approximately 85% of all cases of viral meningitis are now therefore caused by 
enteroviruses (EVs)  (78). 
 
There are few recent data in the UK that attempt to define the incidence, characterise 
the clinical burden or describe the epidemiology of EV infections in infants. The 
introduction of advanced molecular techniques to detect EV infections may have altered 
the clinical epidemiology of EV infections. 
  
Chapter 8 of this thesis will describe longitudinal national data over a 10-year period 
obtained through the national communicable diseases database highlighting a seven-fold 
increase in laboratory confirmed reports of viral meningo-encephalitis. Chapter 9 
provides a detailed analysis of epidemiological trends in EV infections in England and 
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Wales over a similar 12-year period and highlights the impact of increasing use of PCR 
EV disease trends. Chapter 10 outlines a British Paediatric Surveillance Unit (BPSU) 
study which aims to evaluate the clinical burden of EV meningitis in infants less than 90 
days old.  
 
1.3.1 Serotype diversity in the U.K  
 
The last surveillance study conducted in the UK to characterise the molecular 
epidemiology of circulating EV serotypes was conducted over 20 years ago (81). This 
study analysed culture positive laboratory reports between 1975 and 1994 and 
demonstrated that Coxsackie A9, E7, E9, E11, E19 and E30 accounted for 70% all 
culture positive results. Chapter 9 will provide contemporary national data describing 
trends in EV reporting and circulating serotypes. These data show no particular 
predominance of any strain which may reflect the increase in PCR use to identify EV. 
Knowledge of current circulating serotypes is important in identifying any association 
between serotype and phenotype, designing future treatment trials and monitoring 
disease outbreaks. 
 
1.3.2 Clinical disease 
 
The spread of EV occurs predominantly through faecal-oral spread.  Poliovirus 
infections and poliomyelitis have become exceedingly rare in most developed countries 
as a result of routine immunisation programmes  (82,83). The World Health 
Organization (WHO) regions of the Americas and the Western Pacific were certified 
polio-free in 1994 and 2000, respectively. Europe has been declared free of polio since 
2002. No cases of Polio virus 2 have been recorded since 1999 (84). No cases of Polio 3 
have been reported since November 2012 (85). A recent report started that global 
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eradication will be achieved if safety is guaranteed to healthcare workers delivering 
vaccine programmes, maintaining government commitment and continued surveillance 
(86). 
 
Non Polio EV’s are a major cause of infection in children, with up to 10 to 30 million 
infections annually in neonates and young infants (87–89). 
 
EVs replicate in the respiratory tract, small intestine and several other secondary organs. 
Most EVs cause only mild disease including low grade fever, self-limiting rash or 
general malaise. In some instances, the disease manifestations can be more severe and 
include acute flaccid paralysis, myocarditis, meningitis, encephalitis and severe 
generalised infection in the newborn (90).
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1.3.2.1 EV meningitis  
 
Diagnosis on clinical grounds is difficult to establish in neonates. EV meningitis in 
infants is often accompanied by involvement of other organ systems (91). Fever and 
irritability are the most common features and nuchal rigidity rare (92). 
 
CSF pleocytosis is an uncommon finding in infants with EV meningitis. A study in 
South Korea showed that 68%-77% of neonates did not have any evidence of CSF 
pleocytosis (93). Other studies have shown pleocytosis to be absent in 22.3% and 50% 
of all cases of EV meningitis in infants less than a month old (94,95). CSF pleocytosis 
is therefore an unreliable marker of EV meningitis in infants. The lack of pleocytosis 
may be due to immunological immaturity in neonates or the short duration between 
obtaining CSF and disease onset. 
 
Chapter 8 provides the first national longitudinal surveillance study of viral meningitis 
trends for over 20 years. The study highlights that EV causes over 90% of all viral 
meningo-encephalitis cases in infants less than 90 days old in England and Wales. 
These data outline which areas of research should be prioritised in order to better 
understand this condition. 
 
1.3.2.2 Neonatal sepsis syndrome 
 
A prospective, population-based survey in Finland of neonates (up to day 29 of life) 
presenting with suspected systemic infection found that at least 3% of these episodes 
had been caused by EV’s which was the same proportion diagnosed with bacterial 
sepsis during the same period (96).  Risk factors for serious disease include onset in the 
first few days of life, maternal illness before the or at delivery, absence of 
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transplacentally acquired neutralising antibody, prematurity, severe hepatic dysfunction 
and infection with echovirus 11 or coxsackie B viruses (97,98). Factors associated with 
infection may also include lower socioeconomic status, lack of breastfeeding and low 
haemoglobin (99). The most common presenting features associated with neonatal EV 
infection are fever, irritability, poor feeding and lethargy (100,101). Approximately half 
of the infants with neonatal EV infection have evidence of hepatitis or jaundice during 
the course of the illness, while hepatomegaly is detected in around 20% (102). Hepatitis 
is more often associated with Echoviruses (11, 6 ,7 ,9, 14, 17, 19, 21) which can lead to 
persistent hepatic dysfunction and intrahepatic calcification (97).
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1.3.2.3 Long term clinical outcomes  
 
Studies conducted over 20 years ago have reported overall mortality rates ranging 
between 0% and 42% (100,102–104). Neurological, cognitive and developmental delay 
have all been evaluated in follow up studies of infants with EV meningitis (105–108). 
The outcomes in each of these studies show conflicting results. Sells and colleagues 
showed that infants with viral meningitis less than 12 months of age had smaller head 
circumferences, lower IQ’s and delayed language at 1 and 6 years after the infection 
than compared to controls (105), However, studies by Farmer of infants affected by 
coxsackie B5 infection, Bergman of infants less than 12 months with viral meningitis 
and Rorabaugh of infants with aseptic meningitis all showed no neurodevelopmental or 
language delays at one year of follow up (106–108). Each of these studies were 
conducted over 20 years ago and used crude developmental tools, tested at inconsistent 
times after the acute illness and evaluated small numbers of infants with EV meningitis 
caused by different serotypes. 
 
The most recent prospective study to assess developmental outcomes in infants less than 
90 days with EV meningitis was conducted in 1995 in the USA  (109). Sixteen infants 
were enrolled in a case controlled study that included cognitive, developmental, speech 
and language assessments conducted by paediatricians and speech and language 
therapists. The study showed that affected infants only had subtle delays in receptive 
language at 3 years of age.   
 
Chapter 10 will describe the first prospective study in the UK to evaluate the burden and 
outcomes in infants with EV meningitis. This will provide the largest dataset in Europe 
and aims to evaluate the incidence, clinical features, laboratory markers and clinical 
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outcomes in infants less than 90 days.  
 
1.3.3 Treatment  
 
The mainstay of management remains supportive treatment, which may include 
mechanical ventilation, inotropic support, extracorporeal membrane oxygenation, 
cardiac pacemakers and organ transplants in the most severe cases.  
 
1.3.3.1 Antivirals  
 
Developing antivirals against EV has not been a priority for the pharmaceutical 
industry. The biggest EV disease burden in South East Asia is caused by EV 71. 
However, potential revenue from marketing EV71 antivirals may be limited in these 
resource-deprived settings. Manufacturing antivirals against RNA viruses needs to take 
into account their high mutation rate (110). The need for multiple drug agents to act on 
different viral targets to minimise resistance and limited cross genotypic activity further 
increases the challenge to successfully trial new antivirals.  
 
Pleconaril had been shown to inhibit the replication of some enterovirus serotypes and 
rhinoviruses (111). The drug inhibits the uncoating of viral RNA and progeny virions 
during EV replication. Pleconaril has also been shown to have good oral bioavailability. 
A double blind placebo controlled randomised controlled trial of pleconaril in infants up 
to 12 months with suspected EV meningitis showed no clear evidence of efficacy and 
led to early termination of the trial by the pharmaceutical sponsor (112). Infants were 
randomised to receive pleconaril (5mg/kg/dose) orally three times/day for 7 days or 
placebo. Twelve subject received pleconaril and 8 placebo. There were no differences in 
symptoms or length of hospital stay in either group. Overall, 10/12 (83%) in the 
pleconaril group and 6/9 (75%) in the placebo group had adverse events which most 
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commonly included diarrhoea rash and fever. 
 
1.3.3.2 Immunoglobulin (IVIG) 
 
Intravenous immunoglobulin preparations contain neutralising antibodies to EV’s. One 
study showed that administering IVIG prophylactically in all neonates on a neonatal 
unit prevented the spread of echovirus 11 beyond the index case (113) and prevention of 
echovirus 6 in another neonatal outbreak (114). 
 
There have been case reports of IVIG improving clinical outcomes in neonates with 
severe EV meningitis (99,115). However, the only blinded randomised study conducted 
in neonates with enterovirus meningitis infection showed no statistical difference in 
clinical outcome with IVIG (116). Sixteen neonates less than 2 weeks of age and their 
mothers were enrolled. Randomised administration of IVIG (750mg/kg) to 9 neonates 
did not increase neutralisation titers significantly or reduce the daily incidence of 
viraemia or viruria compared to controls (116). 
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1.3.4  Diagnosis
1.3.4.1 PCR 
 
Several studies have shown a high sensitivity ranging between 67% - 100% of EV 
specific PCR assays in comparison to cell culture (116–120) and specifically a 
statistically significant improvement in detection of EV in CSF samples to diagnose 
CNS disease using PCR compared to culture (102,121,122). One step RT-PCR assays 
allow for reverse transcription and DNA amplification in a single, closed reaction tube 
with real time detection of amplicons. One step assays have the added advantage of 
requiring minimal handling of genetic content so reducing the risk of any 
contamination. Several studies have shown high sensitivity and specificity rates using a 
one-step assay (13,123–126). 
 
1.3.4.2 Comparing Non Polio EV RT-PCR and cell culture  
 
The first prospective multicentre study comparing the detection rates of EV and Human 
Parechovirus  (previously known as Echovirus 22 and Echovirus 23) using PCR and cell 
culture in different specimens (CSF, stool, blood, NPA and urine) of paediatric patients 
was published recently (127). A total of 296 nasopharynx, 281 stool, 250 urine, 189 
blood and 141 CSF specimens were available for PCR analysis. 146 nasopharynx, 159 
stool and 80 CSF specimens were available for cell culture. EV was detected in 140 
(49%) and Human Parechovirus (HPeV) in 44 (15%) children. Both EV and HPeV real 
time PCR had a higher sensitivity and negative predictive value than EV and HPeV 
viral culture respectively. EV and HPeV PCR in stool specimens had the highest 
sensitivity (99.2% and 95.1%) of all specimens. An EV was detected in all positive 
patients if RT-PCR was performed on both faeces and CSF samples or in both faeces 
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and urine samples.  
EV replication in the gut can persist for several weeks. Indeed, a number of studies have 
shown that the EV load is higher in faecal samples than CSF during EV meningitis 
(128–130) suggesting that faecal samples should be submitted for EV testing in 
symptomatic patients to increase the diagnostic yield as they are a good target for RNA 
detection. This study also showed that HPeV has a lower detection rate in culture 
compared to EV, which could be due to poor cultivability of certain HPeV serotypes, 
sample quality and low number of viral particles in the specimen at the time of 
sampling. 
 
One of the few national surveillance studies looking at long term trends in enterovirus 
infection was conducted in South Korea (131). The study team evaluated clinical and 
epidemiological disease during 1999 – 2011 which covered a period where three 
different detection methods were used (1999-2004 phase 1 cell culture; 2005 – 2008 
phase II RT-PCR was introduced; 2008 – 2011phase III real time RT-PCR). During 
1999-2005 genotyping was detected using neutralisation assays and since 2005 
sequencing of the VP1 region was used. Cell culture (phase I) detected 20.5% of all EV 
infections, the introduction of RT-PCR (phase II) detected 26.4% and real time RT-PCR 
(phase III) 39.2% of EV was detected. During the 13 year period, 44 different genotypes 
were detected among 3,128 EV positive samples. The 5 main genotypes were EV 71, E 
30, CB5, E6 and CB2 accounting for 14.9%, 12.5%, 9.3%, 8.4% and 6% of the total EV 
infections respectively. The authors note that the increase in number of reports over the 
13 year study period is due to more sensitive molecular assays being used to replace cell 
culture and also due to a number of outbreaks. 
 
Data from chapter 9 was obtained by interrogating the national communicable diseases 
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database. These data show that EV was identified using PCR in 36% in 2001 and rose to 
92% in 2011. This is the first study to highlight that changing diagnostic practices have 
altered the apparent epidemiology of EV infections nationally. Notably, the increased 
use of sensitive molecular assays have led to a year on year increase in EV infections. 
The greatest burden of disease was in infants less than 90 days who accounted for 
almost one quarter of all reported cases across.  These data  have been used to inform a  
BPSU study which will aim to define the clinical burden of EV meningitis in the UK 
and is outlined in chapter 10. 
 
 38 
1.3.4.3 Impact of PCR on clinical practice  
 
Diagnosing EV early can have a clinical and economic impact as this potentially can 
lead to stopping unnecessary antimicrobial drugs, minimising extensive investigations 
and reducing the length of hospital stay. 
 
A recent study in France compared the impact of PCR in managing patients during two 
separate outbreaks of E30 in 2000 and 2005 in a single tertiary unit (132). Molecular 
analysis of the genetic strains and the patient demographics (age and gender) during 
both outbreaks were similar thus implying that management of patients should not have 
varied.  However, PCR was used during the 2005 outbreak and was shown to reduce 
hospital length of stay from 5.4 days to 2.2 days at a cost saving of 322 000 Euros. 
Results of PCR assays were made available within 1.9 days of receipt of the sample. In 
2000, cell cultures inoculated with CSF samples delivered a positive result in 10 days 
and negative result in 14 days at the earliest.   
 
The largest study evaluating the effect of an EV CSF PCR result on length of stay in 
infants under 90 days of life was conducted over 6 enteroviral seasons in a single 
tertiary US centre (133). The authors showed that the length of stay was shorter where 
results were known before discharge. Moreover, a positive PCR result led to a 1.5 day 
decrease in length of stay and 33.7% shorter duration of antibiotic use but a delay in 
delivering the result by 24 hours increased the length of stay by 13.6%.
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1.4 Summary  
 
 
Section 1 of this thesis considers how PCR can be used to better diagnose and manage 
infants with cCMV. This section describes a prospective clinical cohort study evaluating 
the feasibility of targeted testing through the Newborn Hearing Screening Programme 
(NHSP) and outlines strategies to implement national screening.  This section also 
describes a series of experiments which use PCR to define the genetic intervention of 
therapeutic interventions available to manage cCMV. Finally, evidence based guidelines 
to better diagnose and manage infants with cCMV will be outlined. Data presented in 
section 1 will test the hypothesis that advances in molecular virology can significantly 
inform the investigation and management of CNS viral infections as exemplified by 
congenital CMV. 
 
 
 
Understanding how the introduction of molecular diagnostic assays may have influenced 
the epidemiology of EV infection is important in order to prioritise future research. In 
part, the lack of any phase II or III treatment trials is due to our poor understanding of 
the incidence, clinical burden and circulating serotypes of EV in the UK. Section 2 of 
this thesis evaluates how molecular testing has influenced the epidemiology of viral 
meningitis and enterovirus disease in infants less than 90 days old in England and Wales 
over 10 years. Data from these studies will outline the gaps in our understanding of the 
clinical and epidemiological burden of EV meningitis in infants order to inform future 
treatment trials.  
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1.5 Aims 
 
 
The aims of this thesis are to address the following hypotheses:  
 
Section 1: Advances in molecular virology can significantly inform the 
investigation and management of CNS viral infections as exemplified by 
congenital CMV  
 
 Evaluate the feasibility of diagnosing cCMV through clinical integration 
within the Newborn Hearing Screening Programme using salivary PCR 
(chapters 2, 3 and 4). 
 Describe a novel strategy to identify pCMV disease using salivary PCR 
(chapter 5)  
 Conduct a series of molecular sequencing and genotyping studies to better 
understand the medical interventions available to manage cCMV (chapters 6) 
 Outline evidence based management guidelines to identify and treat cCMV 
(chapter 7). 
 
Section 2: Advances in molecular virology are altering the apparent epidemiology 
of CNS viral infections as exemplified by enteroviral infections in infants under 90 
days 
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 Determine the current epidemiology of enterovirus meningitis in infants less 
than 90 days in England and Wales (chapter 8). 
 Determine the current epidemiology of enterovirus infections in infants less 
than 90 days in England and Wales (chapter 9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
 
 
 
     
 
Section 1 
 
Changing management of cCMV 
due to PCR 
 43 
 
Chapter 2 
 
Clinically targeted screening for congenital CMV 
- potential for integration into the National 
Hearing Screening Programme. 
 
 
Acta Paediatr. 2013 Oct;102(10):928-33 
 
https://www.ncbi.nlm.nih.gov/pubmed/23927434 
Congenital CMV screening Kadambari et al.  
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Chapter 3 
 
Evaluating the feasibility of integrating salivary testing for 
congenital CMV into the Newborn Hearing Screening 
Programme in the UK 
 
 
Eur J Paediatr 2015 
 
 
https://www.ncbi.nlm.nih.gov/pubmed/2574311
  
 
 
Chapter 4 
Integrating rapid diagnostic testing for congenital CMV 
into the Newborn Hearing Screening Programme: the 
audiovestibular physician’s perspective 
 
 
 
 
 
 
 
Arch Dis Child Fetal Neonatal Ed. 2015 Sep;100(5):F466-7 
 
https://www.ncbi.nlm.nih.gov/pubmed/26126843
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Chapter 5 
Pre-emptive screening strategies to identify postnatal 
CMV diseases on the neonatal unit 
 
Pediatr Infect 2016 
 
 
https://www.ncbi.nlm.nih.gov/pubmed/27455438 
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Chapter 6  
 
Characterising variation in five genetic loci of 
cytomegalovirus during treatment for congenital 
infection 
 
J Med Virol 2016 
 
https://www.ncbi.nlm.nih.gov/pubmed/27486960 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
45 
Chapter 7  
Fifteen Minute Consultation: Diagnosis and management 
of Congenital CMV 
Arch Dis Child Educ Pract Ed 2016 
 
 
https://www.ncbi.nlm.nih.gov/pubmed/27307463 
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Section 2 
 
Changing epidemiology of enterovirus infections due to 
PCR  
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Chapter 8 
 
 
 
Seven-fold increase in viral meningo encephalitis reports 
in England and Wales during 2004-2013 
 
J Infect 2014 
 
 
 
https://www.ncbi.nlm.nih.gov/pubmed/24887614 
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Chapter 9 
 
Enterovirus infections in England and Wales, 2000-2011: 
The impact of increased molecular diagnostics 
 
Clin Microbiol Infect 2014 
 
https://www.ncbi.nlm.nih.gov/pubmed/25039903 
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Chapter 10 
 
Discussion 
 
 
Data from this thesis supports both hypotheses tested. Molecular virology can inform the 
investigation and management of CNS viral infections as exemplified by congenital CMV. 
Advances in molecular virology are altering the apparent epidemiology of CNS viral 
infections as exemplified by EV infections in infants under 90 days. 
 
The key findings and contributions to the research for each of the publications in this thesis 
are discussed below: 
 
10.1  Section 1 
 
Chapter 2 outlines the criteria that need to be met to screen for cCMV and highlights which 
future research areas need to be prioritised. A novel strategy to test for cCMV through 
integration into the NHSP by obtaining salivary swabs to test for CMV DNA PCR in 
newborns who do not pass their initial hearing screen is detailed. This would ensure that 
CMV related SNHL is detected early in the newborn period and treatment can be started in 
the first month of life in symptomatic infants as per evidence based guidelines. Targeted 
screening would only identify approximately half of all CMV related SNHL cases. The 
CHIMES study team showed that 44% of infants would be missed as they developed SNHL 
after the newborn period (134). Furthermore, Williams and colleagues have shown that 
parental anxiety is not heightened in infants screened and identified with CMV related SNHL 
but no studies have evaluated this in parents of asymptomatic infants (135). However, the 
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review argues that most of the Wilson-Junger criteria to screen for cCMV would be met. The 
review states that it is important to conduct prospective cohort studies to to determine the 
feasibility of integrating salivary testing for cCMV into the NHSP and evaluate whether 
audiology services could conduct the further burden of testing that would arise from 
implementing screening. These areas have not been investigated previously and are essential 
before considering national implementation of any screening programme. Chapters 3 and 4 
examined these areas further. 
 
Chapter 3 describes the first prospective clinical cohort study to evaluate the feasibility of 
integrating testing for cCMV using salivary CMV DNA PCR into the NHSP. The study 
showed that 80% (203/255) of newborns who did not pass their hearing screen had a saliva 
swab taken to test for cCMV. Over 99% of swabs taken delivered a result in the first month 
of life enabling treatment to be started in the appropriate timeframe. Moreover, newborn 
hearing screeners felt confident in obtaining saliva samples after receiving appropriate 
training. Kimberlin and colleagues have recently showed that 6 months of valganciclovir 
therapy causes severe neutopaenia in a fifth of cases and results in modest benefits to 
auditory outcomes (37). Kimberlin highlights that it is essential that are cases are selected for 
treatment carefully and closely monitored. This study had three major limitations. Firstly, 
20% of referrals were made after 21 days of life and thus ineligible. Of the eligible cases, 
20% of parents refused to take part in the study due to most commonly not wanting their 
newborn to be part of a research study. Finally, the initial hearing screen is only performed in 
infants after 34 weeks gestation which means extremely premature babies could not 
participate. These are the first published data showing it is feasible to integrate testing for 
cCMV into the NHSP and thus removes delay in the clinical care pathway by enabling early 
diagnosis and timely treatment. This study already provides the template for local and 
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regional audiology networks in England to screen for cCMV and has been adopted in 
Germany, Ireland, southern Italy and certain states in the USA. 
 
Chapter 4 describes results from a national survey of audiovestibular physicians which 
highlight 69% (n=42/61) of respondents strongly agreed that targeted testing of cCMV 
through integration into the NHSP was a good idea. Furthermore, 80% (n=49/61) thought it 
was feasible to integrate testing. However, 79% (n=41/52) of respondents stated that the 
biggest hurdle to service development would be the increased time taken for physicians to 
manage cases identified through any future screening programme. Chapter 11 will outline a 
multi regional study which aims to address this concern and investigate other areas of 
research, as detailed in chapter 2, that should be prioritised. 
 
Chapter 5 proposes a novel strategy to identify pCMV early using serially collected saliva 
samples in extremely preterm infants. This approach builds on work described in previous 
chapters and aims to provide a coherent methodology using salivary CMV PCR assays to 
identify congenital and postnatally acquired CMV early in at risk populations through serial 
saliva collection. This chapter also provides a concise summary of the risk factors, clinical 
features and investigations that need to be conducted in managing infants with pCMV 
disease. Hamprecht and colleagues have advocated that heat pasteurization of breast milk will 
prevent pCMV transmission to preterm infants (136,137). However, the American Academy 
of Pediatrics recently published guidance that the benefits of giving fresh breast milk in 
seropositive mothers outweighed the risks (138). Only once small placebo controlled trial 
conducted over 20 years ago shows that CMV immunoglobulin reduced the risk of 
transmission compared to placebo (139). A meta analysis by Strippoli and colleagues show 
tat preemptive screening reduces the risk of CMV disease in adult solid organ transplant 
patients (140). Postnatal CMV is a poorly defined illness which affects an extremely 
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vulnerable cohort. This is the first review to offer a strategic mechanism to identify disease 
early using preemptive screening and provides the rationale for a pilot study which is 
discussed in chapter 11. 
Chapter 6 used population based sequencing to characterise the UL97 gene (target for 
ganciclovir), Glycoprotein B (vaccine target) and UL128, UL130 and UL131a (target for 
HIG) genes in infants with symptomatic cCMV who were treated with ganciclovir. This is 
the first study to use serial blood, saliva and urine samples from infected infants treated to 
characterise the gene loci that underpin these medical interventions. This study showed that 6 
weeks of treatment with ganciclovir did not confer resistance and are used to help inform 
treatment guidelines discussed in chapter 7. The region sequenced covered codons 439 – 645 
of the UL97 gene. Chou and colleagues have shown that this area includes all clinically 
relevant ganciclovir mutations (141). It is possible, however, that as yet undefined mutations 
exist outside this region. These results suggest that the rebound in viral load seen at the end 
of treatment is more likely due to the  natural history of CMV dynamic replication rather than 
antiviral resistance (142). Genotyping gB in infected infants reveals multiple CMV genotypic 
variety and the emergence of new strains at 3 months. In contrast to Ross’s study of babies 
not reported to be symptomatic, this study found no evidence of body site 
compartmentalisation, because genetic variants segregated with individual patients rather 
than by body site (143). No maternal samples were available for sequencing and so it was not 
possible to demonstrate the presence of the same genotypes present in a mother and her 
infected newborn as has been shown by Yamamoto et al (144). Future studies could consider 
prospectively collecting samples from other family members to determine if they are the 
source of CMV reinfections during the first year of life. No mutations were identified in the 
UL128, UL130 and UL131a regions of any of the samples sequenced which suggest there 
should be no reduction in binding affinity between monoclonal antibody and virus. These 
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findings have not been published previously and will support the development of vaccine 
design and trials of HIG in susceptible populations. 
 
Chapter 7 consolidates themes discussed in previous chapters and recent treatment trials to 
outline evidence based management guidelines for cCMV which aim to identify disease early 
and treat appropriately. The guidelines recommend commencing 6 months of treatment using 
oral valganciclovir in symptomatic infants if started in the first month of life. Evidence from 
a recently published randomised controlled trial are used to inform the guidelines and 
advocate close monitoring for marrow suppression and renal  impairment throughout 
treatment (37). It is anticipated that these guidelines will be widely adopted across units in 
the UK and minimise variation in treatment amongst clinicians which currently occurs.  
 
Data presented in this section show that molecular tools, such as PCR, can improve diagnosis 
through identifying CMV related SNHL using salivary swabs in newborns who do not pass 
their initial hearing screen and inform management by characterising the molecular 
epidemiology of therapeutic targets and thus inform evidence base guidance. However, 
implementing routine testing for cCMV using salivary PCR may increase diagnostic 
uncertainty amongst clinicians treating mildly symptomatic cases and could heighten parental 
anxiety in parents of asymptomatic newborns. There ae no published data evaluating the 
incidence of treatment resistance in infants who receive 6 months of valganciclovir treatment. 
Analysis of large international datasets through registries is required to improve 
understanding of clinical outcomes of mildly symptomatic infants and better inform which 
newborns to treat.  
 
10.2  Section 2  
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Chapter 8 describes data obtained through interrogation of a national communicable diseases 
database. The study shows a seven-fold increase in viral meningo-encephalitis reposted 
across England and Wales. The burden of disease was highest in infants less than 90 days old 
who account for over a quarter of all cases. Specifically, 92% of all cases of viral meningo-
encephalitis in infants less than 90 days old was due to EV’s. In 2013, the incidence of EV 
meningo-encephalitis was 313/100,000 in infants less than 90 days old compared to the 
overall incidence of viral meningo-encephalits across all age group of 3.9/100,000.  In 2011, 
a study from New York state reported that 340 of 2,357 specimens from patients with 
suspected meningo-encephalitis were positive for at least one virus, including enteroviruses 
(129; 5.5%), EBV (85; 3.6%), HSV (67; 2.8%), and VZV (44; 1.9%)  (145). A prospective 
US cohort study conducted over 20 years ago showed that enteroviruses were grown by cell 
culture to be responsible for 89% of 169 aseptic meningitis cases in <2 year-olds (146).  In 
Brazil, enteroviruses were responsible for around 40% of aseptic meningitis cases, followed 
by HSV-2 (17%), VZV (17%), EBV (12%), HSV-1 (7%) and mumps (7%) (147), while a  
national prospective Spanish study involving 17 hospitals identified a virus in 250 of 581 
meningo-encephalitis cases, including enteroviruses (n=161,66.4%), HSV-1 (n=31, 12.4%), 
VZV (n=28, 11.2%) and HSV-2 (n=3, 1.2%) (148). A major disadvantage of such studies is 
that, while many collected detailed clinical and microbiological data on the confirmed cases, 
most were restricted to specific age-groups and/or did not provide longitudinal data to assess 
trends over time, thus making it difficult to compare with our study. This is the first 
population based longitudinal surveillance study of viral meningo-encephalitis for over two 
decades and demonstrates the significant burden of EV meningo-encephalitis in infants less 
than 90 days old. This study highlights that further research should focus on evaluating the 
clinical burden and long term outcomes of infants who have been affected by EV meningo-
encephalitis in order to inform any future treatment trials. Studies attempting to address this 
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will be discussed in chapter 11. 
 
Chapter 9 investigates the epidemiology of EV infection in more detail. Two large national 
datasets were interrogated. The is one of the largest published studies to describe the impact 
of molecular detection techniques on viral pathogens since being introduced into routine 
clinical practice. The study showed that PCR has significantly altered the apparent 
epidemiology of EV infections. A year on year increase in EV confirmed laboratory reports 
was noted between 2006 – 2011 which coincided with use of PCR. PCR was used to detect 
EV infections in 36% of cases in 2000 and rose to 92% in 2011. Infants less than 3 months 
accounted for almost a quarter of all reported cases during the 12-year surveillance period. 
Compared to overall rates, the incidence of EV infection was almost 100-fold higher <3 
month-olds, far above rates for bacterial infections in this age-group   (149).  In Denmark, the 
incidence of hospital admissions for non-polio EV during 1977-2001 was estimated to be 
10.7 per 100,000 person-years, with the highest incidence in <6 month-olds (38.7 per 
100,000 years)  (150). Comparison is complicated by differences in country-specific clinical 
practice (e.g. threshold for investigating and hospitalising patients with suspected viral 
infections), investigation (e.g. threshold for performing lumbar puncture in patients with 
fever) and diagnosis (e.g. availability of viral cultures or PCR-testing for routine clinical 
samples). The proportion of EV samples undergoing molecular typing remained very low 
through the study and showed no predominance in strain. This study reveals an apparent 
increase in EV disease which is most significant in infants less than 90 days old. Importantly, 
this study highlights in which areas future research should focus. Primarily, knowledge of the 
clinical burden of EV disease in infants less than 90 days old is essential in order to inform 
evidence based management and direct healthcare resources. Prospective data collection 
through clinical and laboratory cohort studies should focus on determining the association 
between circulating serotypes and clinical manifestations in order to inform future treatment 
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trials. A prospective national surveillance study which aims to collect data to fill the gaps in 
our understanding in these areas wil be outlined in chapter 11. 
 
Section 2 shows that PCR has altered the apparent epidemiology of EV infections in infants 
less than 90 months. National surveillance data collected over a decade highlight a seven-fold 
increase in EV meningo-encephalitis as a consequence of increasing PCR use in NHS and 
hospital laboratories. A quarter of all cases occur in infants less than 90 days old. These 
studies are the largest published datasets in Europe to describe longitudinal trends in EV 
disease and evaluate the impact of PCR in disease trends and clearly highlight which future 
areas of research should be priortised. Management of this condition varies considerably 
amongst paediatricians due to the lack of any robust clinical studies to determine the burden 
or long term outcomes of disease. There are currently no phase 2/3 treatment trials in Europe 
in part due to the lack of any current epidemiological data. Large robust prospective 
surveillance studies are necessary to gather these data on order to inform evidence based 
guidance and support future treatment trials. 
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Chapter 11 
Future steps 
 
 
This chapter will detail research I intend to conduct over the next 3 years of my career and 
build on work described earlier in this thesis. I will outline a series of research questions that 
have arisen through this thesis and detail studies that attempt to address these. 
 
 
11.1 Multiregional Implementation of integration of rapid diagnosis for cCMV within the 
Newborn Hearing Screening Programme. The Benefits of Evaluating Salivary Testing for 
congenital CMV (BEST 3 Study) 
 
11.1.1 Research question 
 
How effective is integrating salivary testing for cCMV into the Newborn Hearing Screening 
Programme (NHSP) to prevent audiological deterioration in infants with CMV related 
sensorineural hearing loss (SNHL)? 
 
This proposed study builds on work outlined in chapters 2, 3 and 4. 
 
 
11.1.2 Background 
 
The BEST 3 study will determine the proportion of newborns with CMV related SNHL that 
will be detected through hearing screeners taking a saliva swab to test for CMV DNA PCR 
after not passing the initial hearing screen. Subsequently, it will be possible to determine how 
many newborns will not develop any further audiological deterioration as a consequence of 
being identified and treated early. BEST 3 will be the first study to conduct a cost outcome 
analysis of integrating testing for cCMV into the NHSP.  
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The study team will collaborate with the NHSP and CMV Action to develop an interactive 
educational package for hearing screeners that can be integrated into the NHSP training 
curriculum. The study team will engage with local clinical commissioning groups and other 
stakeholders to develop the infrastructure to test for cCMV by integration within the NHSP 
and build the case for national implementation. Public awareness of CMV remains minimal 
in the UK. The study team will work in collaboration with CMV Action to promote CMV 
awareness to healthcare professionals and pregnant women alike during the antenatal period. 
 
11.1.3 Research Plan 
 
 
Study design 
Prospective observational cohort study 
Primary outcome measures 
 Proportion of newborns with CMV related SNHL who will be identified through 
integrating salivary PCR testing for cCMV into the NHSP.  
 Proportion of newborns with CMV related SNHL identified through integrating 
salivary PCR testing for cCMV into the NHSP that are treated and do not develop 
audiological deterioration  
Inclusion criteria: 
 Infants “referred” for any further audiology testing after completing newborn hearing 
screening 
Methodology  
This study compromises of five work packages: 
1. Multi region screening study  
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The Newborn Hearing screen 
Parents will be given a Pariticipant Information Sheet (PIS) by the newborn hearing screeners 
at the start of their newborns AABR. The AABR typically lasts 45 minutes. Newborns 
referred for further audiological testing after having “no clear response” on the AABR will 
then be given the opportunity to enrol in the study. Newborn hearing screeners will provide 
more detailed information about the study at this point. 
Assent processes  
In this study, assent for the swab would be taken by the NHSP screener. The screener would 
take a sample of saliva using a flocked swab, placing it in the inner surface of the cheek for 
one minute and then into a sterile tube before posting to the CMV Virology Laboratory at the 
Royal Free Hospital. Documentation of assent will be made electronically on the NHSP 
website and an email confirming that the saliva swab has been taken with a confidential study 
number will be sent to the study coordinator.  
Virology  
Newborns diagnosed with cCMV will be seen by the relevant regional paediatric infectious 
diseases specialist. No drug treatment will be offered as part of the study protocol. Antiviral 
therapy will be offered to families with a baby with symptomatic cCMV by regional 
Paediatric Infectious Disease services following national guidelines (50).  
Negative result processing  
Negative results will be sent from the virology department at the Royal Free Hospital to the 
study coordinator who will record the result on eSP and post results to the parents and G.P.  
Positive result processing  
Laboratory personnel will call and email both the study coordinator and local PID specialist 
with the results of any positive swabs on the same day as processing the sample. In the event 
of obtaining a positive CMV result, the PID specialist will liaise with the local audiology 
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team to expedite the newborns definitive audiological assessment. This is already current 
practice and part of routine clinical care.  
2. Education programme   
The educational programme will be conducted in conjunction with the NHSP Training team 
and CMV Action. CMV Action will provide “funding in kind” to help develop the 
programme.  
The study team in collaboration with the NHSP and CMV Action will develop a 
comprehensive educational programme for hearing screeners taking part in the study. All 
hearing screeners are required to pass an Objective Structured Clinical Examination (OSCE) 
and online assessment prior to being certified to screen. This educational package will pilot 
material that may be used in the formal hearing screener training as part of any future 
national implementation. A two hour study session was delivered to screeners during BEST 
2. The session has since been tailored using written and verbal feedback from screeners. A 
study specific training session will be given at each site. This will include didactic teaching 
(overview of importance of testing for cCMV), case based discussions (2-3 case based 
sessions with role play of “real-life scenarios” and feedback) and study specific handouts. 
3. Health economic analysis  
This programme of work will include a health economic assessment which will estimate the 
cost-effectiveness of the enhanced diagnostic pathway compared to current standard practice 
in a large cohort. The cost-effectiveness analysis will take into account the audiological, 
neurocognitive and associated health benefits expected in patients treated through the 
proposed pathway. These benefits will be compared to the direct health costs of the actual 
expenditure of testing, confirmation of diagnosis and subsequent treatment of diagnosed 
cases. Moreover, the model will take into account recent data from a large randomised 
controlled trial which showed that 6 months of oral valganciclovir provided improved 
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audiological and cognitive outcomes at 12 and 24 months of life (37). The cost-effectiveness 
analysis will follow the NICE guidelines for health technology assessment. 
4. Commissioning consultation  
The study team will engage with local clinical commissioning groups within the five regions 
using a structured questionnaire to understand and develop the framework to implement 
integration of cCMV testing into the NHSP established clinical care pathway.  
5. Attitudinal work  
All newborn hearing screeners in England will be invited to complete a brief 5 point Likert 
confidence questionnaire at the start and end of the study in order to assess attitudes and 
confidence towards testing for cCMV. 
 
 
11.2 Pre-emptive screening of preterm babies using salivary PCR to identify and manage 
postnatal CMV on the neonatal unit (POPS CMV study)  
 
11.2.1 Research question  
 
Is it feasible to collect saliva swabs routinely on neonatal units to detect early, asymptomatic, 
postnatal CMV infection? 
 
This proposed study builds on work outlined in chapter 5. 
 
  
11.2.2 Background 
 
 
This single centre study will provide preliminary pilot data that will be used to scrutinise any 
association between viral kinetics and onset of disease which might assist in defining a group 
of babies that could benefit from early antiviral therapy to prevent severe CMV-related 
morbidities. Data will also be collected to better understand the clinical burden of pCMV and 
outcomes at discharge.  
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It is hoped that results from this pilot study will be used to gain external funding to facilitate 
collaboration with other centres in the U.K and USA on perinatal CMV. The Collaborative 
Antiviral Study Group (CASG) are currently enrolling into a treatment study to assess the 
pharmacokinetics and pharmacodynamics of ganciclovir in preterm infants 
(https://clinicaltrials.gov/ct2/show/NCT01602614?term=david+kimberlin&rank=1). It has 
not however been possible to collaborate with the group as there have been no studies in the 
U.K that have demonstrated the burden of CMV disease in preterm infants. It is hoped that 
new data might allow for collaboration with the CASG or provide information sufficient to 
power a study in other U.K sites.  
 
11.2.3 Research plan 
 
Study design 
Prospective observational cohort study  
Primary outcome measures 
 Assess the feasibility of pre emptive screening for pCMV on NICU 
 Gather pilot data to assess any association between viral load, gestational age and 
clinical features in infants with pCMV 
Inclusion criteria 
 Infant <32 weeks or <1500gm who has CMV DNA isolated on saliva swab taken 
during weekly screening after 21 days of life 
Methodology 
Identification of infants: The neonatal team will inform the study nurse/research fellow that 
an infant <32 weeks gestation/<1500g has been admitted to the neonatal unit 
Consent: Patient Information Sheet will be given to parents for all eligible participants as part 
of admission and the neonatal team will ask parents if they are happy to be approached to 
discuss the study further. Informed written consent for weekly swabs and collection of data 
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will be taken by the study team. Neonatal nursing staff will take a sample of saliva using a 
flocked swab, placing it in the inner surface of the cheek for one minute and then into a 
sterile tube before posting to the Royal Free Hospital, London on a set day each week. 
Samples will be taken within the first 14 days of life and then on a weekly basis from 22 days 
of life until discharge from NICU.  
Laboratory processes: Swabs will be posted for immediate testing for CMV DNA by real 
time quantitative PCR.  
Result processing: Positive results will be telephoned within 24 hours and negative results 
emailed weekly to the study coordinator from the laboratory. The study nurse/research fellow 
will inform the neonatal team and parents immediately in the event of a positive result.  
Data collection: All clinical and demographic data will be anonymised, collected and stored 
onto a password protected Excel spreadsheet. Data will be backed up onto the St George’s, 
University of London shared drive which is backed up centrally every 24 hours by the 
university IT.  
Clinical samples: Parents will be consented to collect serial blood, saliva and urine samples 
from cases where saliva PCR is positive. This will enable to staging and monitoring if CMV 
disease progression. 
 
11.3  Characterising the burden of enterovirus and parechovirus meningitis in infants less 
than 90 days old in the UK and Republic of Ireland (BPSU EV/HPeV meningitis 
Surveillance Study) 
 
 
11.3.1. Research question  
 
What is the clinical burden (rate of hospitalisation including NICU/PICU admission) of 
enterovirus (EV) and parechovirus (HPeV) meningitis in the Untied Kingdom and Republic 
of Ireland? 
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This proposed study builds on work outlined in chapters 8 and 9  
 
 
11.3.2 Background 
 
 
This will be the first UK study to link the molecular types of EV/ HPeV circulating in the UK 
and Ireland with clinical disease, such as severity, laboratory markers or outcomes. This 
provides a unique opportunity to prospectively collect clinical information and understand 
whether specific strains might be associated with more severe infection in young infants. The 
results of the BPSU study may also provide an evidence-base for national guidance on the 
prevention, investigation and management of EV/HPeV infections in young infants. The 
study will allow comparison between disease severity and source of positive specimens. It 
will also be able to assess whether the disease severity is associated with the amount of virus 
present in the blood and/or CSF by measuring the viral load. In the absence of any licenced 
medication it is unclear what proportion of clinicians use blood products such as 
immunoglobulins to affect the course of disease and what the outcomes at discharge are. The 
BPSU study may be able to identify possible impact of such therapies on the outcome of 
disease. Finally, this BPSU study will serve to promote awareness of EV/ HPeV meningitis 
amongst paediatricians and, thus, aim to improve case detection, recognition and 
management. 
 
11.3.3 Research plan 
 
 
Study design 
Prospective enhanced national surveillance study  
 
Primary outcome measure 
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• To estimate age-group specific hospitalisation rates per 100,000 childhood population 
for enterovirus (EV) and parechovirus (HPeV) meningitis 
 
Inclusion criteria  
Any infant aged less than 90 days old with clinical symptoms of meningitis* AND laboratory 
confirmation of enterovirus or parechovirus from any site** 
* fever (≥38 degrees Celsius), coma, seizures, neck stiffness, apnoea, bulging fontanelle, 
irritability, lethargy, poor feeding 
**CSF, blood, stool, throat, peri-anal swab 
Exclusion criteria  
Isolation of enterovirus or parechovirus with no clinical symptoms of meningitis*.  
* fever (≥38 degrees Celsius), coma, seizures, neck stiffness, apnoea, bulging fontanelle, 
irritability, lethargy, poor feeding 
 
Methodology  
Paediatricians will be asked to notify any cases in the previous month through the BPSU 
orange card system. At the same time, potential cases will also be identified using LabBase2, 
a voluntary electronic database used by almost all hospital microbiologists in the UK to 
report clinically significant infections to the PHE, as well as the PHE Virus Reference 
Department (VRD) electronic database, MOLIS. LabBase2 and MOLIS notification will be 
compared with the BPSU cases using a number of identifiers including NHS number, date of 
birth, gender, admitting hospital, date of diagnosis and source of sample. Paediatricians and 
microbiologists will also be reminded to submit the EV/HPeV specimen to the PHE virus 
reference laboratory for molecular typing if this has not already been done. No additional 
samples will be taken from patients. Meningitis charities, including Meningitis Research 
Foundation and Meningitis UK/Meningitis Trust, have been informed of the study and agreed 
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to promote awareness on their website. The study team will not be contacting any parent 
directly. 
In keeping with existing national guidance, NHS hospital microbiology labs are advised to 
submit all positive EV/HPeV strains to PHE Virus Reference Department (VRD) for 
molecular typing.  Before starting the study, the study team will write to all microbiologists 
through the national microbiology network to promote the study and remind them to submit 
all positive EV/HPeV clinical samples to PHE VRD for molecular typing, especially in 
infants less than 90 day-olds. For all cases reported through the BPSU, the study team will 
also remind the microbiologist of the reporting hospital in writing to ensure all positive 
clinical samples are submitted to PHE VRD. 
 
 
11.4 Neurodevelopmental follow up of enterovirus and parechovirus meningitis in infants 
less than 90 days old 
 
 
11.4.1 Research question 
 
What are the neurodevelopmental outcome of enterovirus (EV) and human parechovirus 
(HPeV) meningitis in infants less than 90 days old? 
 
This proposed study builds on work outlined in chapters 8 and 9  
 
 
11.4.2 Background 
 
This study will be the first in Europe to comprehensively evaluate neurodevelopmental 
outcomes in infants with EV and HPeV meningitis. It will also provide a unique opportunity 
to link molecular subtype with phenotype. Data from this study will be used to inform the 
evidence base to manage infants with EV and HPeV meningitis beyond the inpatient setting 
and define which healthcare needs are required for this vulnerable population. Furthermore, 
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an accurate data of the natural history of the condition is crucial to evaluate potential future 
developments of anti-viral and immunotherapeutic strategies.   
 
 
11.4.3 Research plan 
 
 
Study design 
Prospective observational cohort study  
Primary outcome measures 
 Determine if babies who had meningitis caused by viruses (caused by enterovirus or 
parechovirus) in the first three months of life have developmental delay in early 
childhood 
 Define any link between developmental outcomes of infants with enterovirus or 
parechovirus meningitis and specific genetic type of virus 
 Assess the effects of enterovirus and parechovirus meningitis in young infants on the 
quality of life of both the survivors and the adult family members of survivors 
 
Methodology 
Eligible infants will be identified using Public Health England (PHE) LabBase2 or Molis 
database (PHE’s national database). UK National Health Service hospital microbiology 
laboratories in England and Wales routinely report enterovirus and parechovirus cases 
pathogens electronically on a voluntary basis to PHE. Both datasets do not contain clinical 
data. 
 
The study team will contact the family’s GP to inform them that we are proposing to 
approach the family regarding this study. Unless the GP indicates otherwise, families will 
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then be contacted by post and provided with a patient information leaflet on the study and 
invited to participate. If parents agree, the study team will discuss the study procedures in 
more detail, provide the opportunity for parents/carers to ask questions and arrange a time 
and date for the study visit. If the parents have not replied to the original invitation one 
further invitation letter will be sent after approximately two weeks. 
Parents will be asked to provide written consent for themselves and their child. No study 
procedures will be performed until written informed consent is given. All individuals and 
families will be free to withdraw from participation at any time without giving a reason and 
without this affecting the ongoing care, and this will be explained in the consenting process. 
Identifying cases through in this manner will ensure that this population based study 
minimises any risk of selection bias. This study will provide the largest and most 
comprehensive dataset in Europe of infants with neurodevelopmental outcomes following 
enterovirus/parechovirus meningitis as an infant. It will therefore be possible to address the 
study aims as outlined above. This will be the first study to link which 
enterovirus/parechovirus types are associated with poorest outcomes and evaluate the effects 
of immune modulating therapies on long term outcomes. 
 
Neurodevelopmental assessments  
The children will have an assessment of their cognitive, language and motor development 
using the third edition of the Bayley Scales of Infant Development (BSID III). This 
assessment is done on one occasion and takes approximately 60 – 90 minutes. A member of 
the study team with training in developmental paediatrics and use of BSID III will perform 
the assessment in the child’s home. If any of the children are aged over 36 months their 
current progress will be evaluated using information from their parents, general practitioner 
and any educational or paediatric assessments which have taken place previously.  
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Basic information on neurological status, functional disabilities (hearing, vision and speech 
and language), general health problems (respiratory, renal and gastrointestinal function) and 
growth will be collected at the same time as the Bayley Scales is performed. This information 
will be collected using questions from the 2008 Health Status Questionnaire (HSQ).  
Quality of life assessments 
Parents and other family members (over the age of 16 years) of survivors of bacterial 
infections who have been recruited to the follow-up study will be invited to complete a 
PEDsQL to assess the health status of their child by proxy. The questionnaire will be given to 
the adult with parental responsibility for the child by the study team at the start of the 
assessment visit. The same assessment will also be independently completed by a member of 
the study team during the visit. The same adult will be asked to complete an EQ-5D-5L 
questionnaire to assess their own health status. Additional forms will be provided for other 
family members who are eligible to participate (i.e. over 16 years of age). The study team 
will collect any questionnaires that have been completed by the end of their visit and provide 
a stamped addressed envelope for the return of any additional questionnaires.  
Results 
The GP (with parental permission) and parents of each child will receive a copy of the results 
of the child’s assessment. A paediatric doctor from the study team will be available to answer 
questions relating to the assessment. If any areas of concern, or need for specialist referral, 
are identified this will be included in the assessment report sent to the child’s GP so that the 
appropriate referral can be made locally. Information about relevant support groups (e.g. 
Meningitis Research Foundation) will also be provided to them.  
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